Literature DB >> 30159656

The midrange left ventricular ejection fraction (LVEF) is associated with higher all-cause mortality during the 1-year follow-up compared to preserved LVEF among real-world patients with acute heart failure: a single-center propensity score-matched analysis.

Josip Anđelo Borovac1, Katarina Novak2, Josko Bozic3, Duska Glavas2,4.   

Abstract

The objectives of the study were to characterize and compare different acute heart failure (AHF) subgroups according to left-ventricular ejection fraction (LVEF) in terms of all-cause mortality and HF-related readmissions during the 1-year follow-up (FU). Three hundred and fifty-six AHF patients admitted to Cardiology ward and/or CCU were retrospectively included in the study and analyzed during the 1-year FU. Patients were stratified according to LVEF as those with preserved (HFpEF), midrange (HFmrEF) and reduced LVEF (HFrEF). During the FU period, 148 (43.3%) patients died, and 116 HF-related readmission events were recorded. HFmrEF group had significantly higher standardized all-cause mortality rate, unadjusted for age, compared to HFpEF group and significantly lower than HFrEF group (41 vs. 18 and 41 vs. 62.5 events per 100 patient-years; χ2 = 41.08, p < 0.001 and χ2 = 16.62, p < 0.001, respectively). A propensity score-matched analysis in which all HF groups were matched for age and other covariates confirmed that HFmrEF group had significantly higher all-cause mortality rate than HFpEF group (χ2 = 15.66, p < 0.001) while no significant differences in readmission rates were observed across all groups (p = NS). The hazard risk for a composite endpoint of death and readmission was highest in HFrEF group (HR 6.53, 95% CI 3.53-12.08, p < 0.001), followed by HFmrEF group (HR 3.30, 95% CI 1.86-5.87, p < 0.001) when compared to HFpEF group set as a reference. Among AHF patients, the HFmrEF phenotype was associated with significantly higher all-cause mortality compared to HFpEF, during the 1-year FU. This finding might implicate more stringent clinical approach towards this patient group.

Entities:  

Keywords:  HFmrEF; Heart decompensation; Heart failure; Mortality; Patient readmission

Mesh:

Year:  2018        PMID: 30159656     DOI: 10.1007/s00380-018-1249-7

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  44 in total

1.  Acute heart failure syndromes: current state and framework for future research.

Authors:  Mihai Gheorghiade; Faiez Zannad; George Sopko; Liviu Klein; Ileana L Piña; Marvin A Konstam; Barry M Massie; Edmond Roland; Shari Targum; Sean P Collins; Gerasimos Filippatos; Luigi Tavazzi
Journal:  Circulation       Date:  2005-12-20       Impact factor: 29.690

Review 2.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur J Heart Fail       Date:  2008-09-16       Impact factor: 15.534

3.  The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%).

Authors:  Carolyn S P Lam; Scott D Solomon
Journal:  Eur J Heart Fail       Date:  2014-09-11       Impact factor: 15.534

4.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

5.  Pharmacological strategies in heart failure with preserved ejection fraction: time for an individualised treatment strategy?

Authors:  Frédéric Schnell; Erwan Donal
Journal:  Heart       Date:  2017-08-18       Impact factor: 5.994

6.  Is ejection fraction in heart failure a limitation or an opportunity?

Authors:  Lars H Lund; Ola Vedin; Gianluigi Savarese
Journal:  Eur J Heart Fail       Date:  2018-01-15       Impact factor: 15.534

7.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

Authors:  Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

Review 8.  Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions.

Authors:  Jeffrey J Hsu; Boback Ziaeian; Gregg C Fonarow
Journal:  JACC Heart Fail       Date:  2017-10-11       Impact factor: 12.035

9.  Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.

Authors:  Richard K Cheng; Margueritte Cox; Megan L Neely; Paul A Heidenreich; Deepak L Bhatt; Zubin J Eapen; Adrian F Hernandez; Javed Butler; Clyde W Yancy; Gregg C Fonarow
Journal:  Am Heart J       Date:  2014-07-22       Impact factor: 4.749

10.  Who are patients classified within the new terminology of heart failure from the 2016 ESC guidelines?

Authors:  Benoit Delepaul; Guillaume Robin; Clément Delmas; Thomas Moine; Adrien Blanc; Pauline Fournier; Aénora Roger-Rollé; Guillaume Domain; Clémence Delon; Charles Uzan; Rabah Boudjellil; Didier Carrié; Jérôme Roncalli; Michel Galinier; Olivier Lairez
Journal:  ESC Heart Fail       Date:  2017-01-31
View more
  2 in total

1.  Factors affecting hospital readmission heart failure patients in Japan: a multicenter retrospective cohort study.

Authors:  Takuya Umehara; Nobuhisa Katayama; Miwako Tsunematsu; Masayuki Kakehashi
Journal:  Heart Vessels       Date:  2019-09-13       Impact factor: 2.037

2.  Special prognostic phenomenon for patients with mid-range ejection fraction heart failure: a systematic review and meta-analysis.

Authors:  Pan Guo; Jian-Feng Dai; Chao Feng; Shu-Tao Chen; Jin-Ping Feng
Journal:  Chin Med J (Engl)       Date:  2020-02-20       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.